PHARNEXT

110 articles about PHARNEXT

• Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors

  12/23/2021

  Pharnext SA announces the appointment of Dr. Elisabeth Svanberg MD, PhD to succeed Michel de Rosen as Chairman of the Board of Directors effective January 1st, 2022.

• Pharnext Appoints Dr. Burkhard Blank as New Chief Medical Officer and Head of Research & Development

  11/22/2021

  Pharnext SA announces the appointment of Dr. Burkhard Blank as Chief Medical Officer and Head of Research & Development effective January 1, 2022.

• Pharnext Confirms Details for 2021 Hybrid Research & Development Day

  10/21/2021

  Event to be held in person in New York, or virtually via a simultaneous live webcast, on Wednesday October 27, 2021 at 8:30 am ET/ 2:30 pm CET

• Pharnext Strengthens its Management Team with Three Key Appointments to Support Ongoing Development of PXT3003 Toward Approval and Commercialization

  10/19/2021

  Pharnext SA is pleased to announce the strengthening of its senior management team with the appointments of Raj Thota, as Chief Manufacturing Officer and Head of CMC, Abhijit Pangu as the Head of Regulatory Affairs and the promotion of Xavier Paoli to Chief Operating Officer.

• Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A, the PLEO-CMT Trial, Published in the Orphanet Journal of Rare Diseases

  10/18/2021

  Pharnext SA today announces the publication of the data from the Company's first phase III placebo-controlled clinical study of PXT3003 in Charcot-Marie-Tooth disease Type 1A ('CMT1A')

• Pharnext Reports First Half 2021 Financial Results

  10/14/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its financial results for first-half of 2021.

• Pharnext to Host 2021 Hybrid Research & Development Day

  10/6/2021

  Pharnext SA will be hosting a hybrid Research and Development day on Wednesday, October 27, 2021, from 8:30 to 10:30 a.m. ET / 2:30 to 4:30 p.m. CET.

• Piers Morgan Joins Pharnext's Board of Directors

  7/15/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its Board of Directors has appointed Piers Morgan as a new, independent, non-executive member following a comprehensive search and selection process.

• Pharnext Announces First Patient Enrolled in Europe in the PREMIER Trial, its Pivotal Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')

  7/12/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces the enrollment of the first patient in Europe in its pivotal Phase III clinical study of PXT3003 in Charcot-Marie-Tooth disease type 1A.

• Pharnext: Shareholder Letter - June 21, 2021

  6/21/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, published a Letter to Shareholders from its Chief Executive Officer, Dr. David Horn Solomon.

• Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study

  6/7/2021

  Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth Disease Type 1A

• Pharnext Reports Financial Results for Year-End 2020

  4/27/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces its financial results for the fiscal year ended December 31, 2020.

• Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A ('CMT1A')

  3/31/2021

  Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, announces that the first subject has been enrolled in its pivotal Phase III clinical study of PXT3003 in the U.S. at the Austin Neuromuscular Center.

• Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors

  2/4/2021

  European investors have also provided written indication of strong interest for the potential of additional €25 million in similar convertible bonds, depending on future market conditions

• Pharnext 2019 Universal Registration Document Approved by AMF

  11/10/2020

  Pharnext SA announced that its 2019 Universal Registration Document has been approved by the Autorité des Marchés Financiers on November 9, 2020 under number N° R. 20-029.

• Pharnext to Host Research and Development Day on October 13, 2020

  9/29/2020

  Pharnext SA announced that it will host a research and development day focused on the company's development efforts related to its lead asset, PXT3003, in Charcot-Marie-Tooth disease type 1A on Tuesday, October 13, 2020, from 8:00 - 10:30 a.m. ET / 2:00 - 4:30 p.m. CET.

• 

  BioSpace Global Roundup, April 23

  4/23/2020

  Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.

• Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its PleotherapyTM Platform

  3/23/2020

  Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the identification of 97 frequently prescribed drugs as potential candidates to be repositioned for treating COVID-19 through the use of its Pleotherapy platform.

• 

  Biopharma Industry News for March 23: Update on the Novel Coronavirus

  3/23/2020

  A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.

• Pharnext establishes an equity line facility with Kepler Cheuvreux

  11/19/2019

  Pharnext SA, a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, announced the establishment of an equity line facility to enhance the Company's financial flexibility and improve liquidity for shareholders.